| [1] Oyston P C, Fox M A, Richards S J, et al. Novel peptide therapeutics for treatment of infections. J Med Microbiol, 2009, 58(Pt 8):977-987.
[2] Mader J S, Hoskin D W. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs, 2006, 15(8):933-946.
[3] Aley S B, Zimmerman M, Hetsko M, et al. Killing of Giardia lamblia by cryptdins and cationic neutrophil peptides. Infect Immun, 1994, 62(12):5397-5403.
[4] Palermo C M, Bennett C A, Winters A C, et al. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. Leuk Res, 2008, 32(4):633-642.
[5] Apponyi M A, Pukala T L, Brinkworth C S, et al. Host-defence peptides of Australian anurans: structure, mechanism of action and evolutionary significance. Peptides, 2004, 25(6):1035-1054.
[6] Johnstone S A, Gelmon K, Mayer L D, et al. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des, 2000, 15(2):151-160.
[7] Nakamura M, Iwasaki T, Tokino S, et al. Development of a bioactive fiber with immobilized synthetic peptides designed from the active site of a beetle defensin. Biomacromolecules, 2011, 12(5):1540-1545.
[8] Kuwata H, Yip T T, Yip C L, et al. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun, 1998, 245(3):764-773.
[9] Kulkarni M M, McMaster W R, Kamysz W, et al. Antimicrobial peptide-induced apoptotic death of leishmania results from calcium-dependent, caspase-independent mitochondrial toxicity. J Biol Chem, 2009, 284(23):15496-15504.
[10] Kindrachuk J, Scruten E, Attah-Poku S, et al. Stability, toxicity, and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers. Biopolymers, 2011, 96(1):14-24.
[11] Menon J, Soto-Pantoja D R, Callahan M F, et al. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res, 2007, 67(6):2809-2815.
[12] Kim S J, Nian C, McIntosh C H. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem, 2007, 282(47):34139-34147.
[13] Mizejewski G J. The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent. Cancer Biother Radiopharm, 2007, 22(1):73-98.
[14] Sinha S, Malonia S K, Mittal S P, et al. Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element. EMBO J, 2010, 29(4):830-842.
[15] Bell H S, Dufes C, O’Prey J, et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest, 2007, 117(4):1008-1018.
[16] Pinto M, Perez J J, Rubio-Martinez J. Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins. J Comput Aided Mol Des, 2004, 18(1):13-22.
[17] Ozawa T, Natori Y, Sako Y, et al. A minimal peptide sequence that targets fluorescent and functional proteins into the mitochondrial intermembrane space. ACS Chem Biol, 2007, 2(3):176-186.
[18] Fazio N, Cinieri S, Lorizzo K, et al. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev, 2010, 36(Suppl 3):87-94.
[19] Bawolak M T, Gera L, Morissette G, et al. B-9972 (D-Arg--bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg--bradykinin): pharmacologic profile and effective induction of receptor degradation. J Pharmacol Exp Ther, 2007, 323(2):534-546.
[20] Bieker R, Kessler T, Schwoppe C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood, 2009, 113(20):5019-5027.
[21] Reardon D A, Neyns B, Weller M, et al. Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol, 2011, 7(3):339-354.
[22] Khalili P, Arakelian A, Chen G, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther, 2006, 5(9):2271-2280.
[23] Wu Z Z, Li P, Huang Q P, et al. Inhibition of adhesion of hepatocellular carcinoma cells to basement membrane components by receptor competition with RGD- or YIGSR-containing synthetic peptides. Biorheology, 2003, 40(4):489-502.
[24] Gomar F, Orozco R, Villar J L, et al. P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial. Int Orthop, 2007, 31(1):93-99.
[25] Wang W, Shao R, Wu Q, et al. Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide. Mol Imaging Biol, 2009, 11(6):424-433.
[26] Sato S, Kopitz C, Schmalix W A, et al. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett, 2002, 528(1-3):212-216.
[27] Campbell N E, Greenaway J, Henkin J, et al. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia, 2010, 12(3):275-283.
[28] Sulochana K N, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des, 2007, 13(20):2074-2086.
[29] Piro O, Broze G J. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation, 2004, 110(23):3567-3572.
[30] Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol, 2003, 139(10):1325-1332.
[31] Casares N, Lasarte J J, de Cerio A L, et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol, 2001, 31(6):1780-1789.
[32] Petrova E E, Valyakina T I, Komaleva R L, et al. Glucosaminylmuramyl dipeptide potentiates the effects of tumor necrosis factor-alpha and cisplatin on transformed cells in vitro. Bull Exp Biol Med, 2007, 143(2):251-254.
[33] Luan Y, Wang Q, Liu N, et al. Synthesis and activity evaluation of a new bestatin derivative LYP2 as an aminopeptidase N inhibitor. Anticancer Drugs, 2011, 22(1):99-103.
[34] Kukowska-Kaszuba M, Dzierzbicka K, Serocki M, et al. Solid phase synthesis and biological activity of tuftsin conjugates. J Med Chem, 2011, 54(7):2447-2454.
[35] Barna B P, Thomassen M J, Zhou P, et al. Activation of alveolar macrophage TNF and MCP-1 expression in vivo by a synthetic peptide of C-reactive protein. J Leukoc Biol, 1996, 59(3):397-402.
[36] Tower A M, Trinward A, Lee K, et al. AFPep, a novel drug for the prevention and treatment of breast cancer, does not disrupt the estrous cycle or fertility in rats. Oncol Rep, 2009, 22(1):49-56.
[37] Papo N, Seger D, Makovitzki A, et al. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res, 2006, 66(10):5371-5378.
[38] Pei X H, Bai F, Smith M D. p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers. Cancer Res, 2007, 67(7):3162-3170.
[39] Salomonsson E, Thijssen V L, Griffioen A W, et al. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J Biol Chem, 2011, 286(16):13801-13804. |
